Glycopeptides (Vancomycin and Teicoplanin) and Lipoglycopeptides (Telavancin, Oritavancin, and Dalbavancin)

Keyphrases

• Vancomycin 100%
• Teicoplanin 100%
• Glycopeptides 100%
• Telavancin 100%
• Lipoglycopeptide 100%
• Dalbavancin 100%
• Oritavancin 100%
• Methicillin-resistant Staphylococcus Aureus Infection 75%
• Enterococcus 50%
• In Vitro Activity 50%
• Endocarditis 50%
• Skin Structure Infections 50%
• Loading Dose 50%
• Acute Bacterial Skin 50%
• Hospital-acquired 25%
• Ventilator-associated Pneumonia 25%
• Skin Infection 25%
• Serum Levels 25%
• High Dose 25%
• Nephrotoxicity 25%
• Antibiotics 25%
• Staphylococcus Aureus 25%
• Fever 25%
• Bacteremia 25%
• Methicillin-resistant Staphylococcus Aureus 25%
• Osteomyelitis 25%
• Once-daily 25%
• Duration of Therapy 25%
• Should Be Given 25%
• Hospital Setting 25%
• Optimal Dosing 25%
• Clostridioides Difficile 25%
• Gram-positive Bacteria 25%
• Current Guidelines 25%
• Vancomycin-resistant Enterococci 25%
• Terminal Half-life 25%
• Rash 25%
• Outpatient Treatment 25%
• Renal Impairment 25%
• Synthetic Derivatives 25%
• Methicillin-resistant Staphylococcus Aureus Pneumonia 25%
• Oral Vancomycin 25%
• Optimal Monitoring 25%
• Enterococcal Infections 25%
• C. Difficile Colitis 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Methicillin Resistant Staphylococcus Aureus Infection 100%
• Vancomycin 100%
• Teicoplanin 100%
• Glycopeptide 100%
• Telavancin 100%
• Dalbavancin 100%
• Oritavancin 100%
• Side Effect 75%
• Infection 50%
• Endocarditis 50%
• Nephrotoxicity 25%
• Antibiotics 25%
• Staphylococcus aureus 25%
• Methicillin-Resistant Staphylococcus Aureus 25%
• Enterococcus 25%
• Syndrome 25%
• Osteomyelitis 25%
• Bloodstream Infection 25%
• Clostridium Difficile Infection 25%
• Rash 25%
• Streptococcus 25%
• Gram Positive Bacterium 25%
• Skin Infection 25%
• Enterococcal Infection 25%
• Ventilator Associated Pneumonia 25%
• Vancomycin-Resistant Enterococcus 25%